FDA
TALK PAPER

Food and Drug Administration
U.S. Department of Health and Human Services
Public Health Services 5600 Fishers Lane Rockville, MD 20857

FDA Talk Papers are prepared by the Press Office to guide FDA personnel in responding with consistency and accuracy to questions from the public on subjects of current interest. Talk Papers are subject to change as more information becomes available.

 

T99-31				  Print Media:         301-827-6242
July 12, 1999			  
				       Consumer Inquiries:  301-INFO-FDA

FDA APPROVES FIRST TOPICAL TREATMENT FOR HEARTWORM PREVENTION FOR DOGS AND CATS

FDA has approved the first topical drug--Revolution (Selamectin)--for the prevention of heartworm disease in dogs and cats six weeks of age and older. Revolution is also the first drug to combine heartworm prevention as well as the prevention and control of adult fleas and their eggs. Although heartworms and fleas are the most significant parasites that Revolution has activity against, the drug is also effective against ear mites in cats and dogs, sarcoptic mange (also known as scabies) in dogs, and intestional roundworm and hookworm infections in cats.

The drug is applied topically once a month. The duration of treatment depends on the type of parasitic infection.

In clinical trials, Revolution was shown to be safe and effective, with minimal side effects, and was well tolerated by healthy dogs and cats. Caution must be used when treating sick, debilitated or underweight animals.

Revolution will be sold by Pfizer Inc. of New York, N.Y. beginning this fall. It will be available only on the order of a licensed veterinarian.

####

Link to FDA HOME PAGE